Immuneering Shares Surge Ahead of Key Clinical Data Release

Shares of clinical-stage biopharmaceutical company Immuneering Corporation are posting significant gains today, advancing 2.46% to trade at $8.34. This upward momentum arrives at a pivotal moment, as the market anticipates the release of updated trial results scheduled for September 25th.

The company announced it will present new overall survival (OS) data from its Phase 2a study evaluating a combination therapy for pancreatic cancer. This dataset will feature a median follow-up period of nine months. The trial involves 34 patients with newly diagnosed pancreatic cancer who were treated with Atebimetinib in combination with a standard chemotherapy regimen.

This data release follows highly promising interim results announced in June 2025, which demonstrated a six-month survival rate of 94% for patients on the combination therapy. This figure notably surpasses the typical 65% survival rate associated... Read more...